Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 12, 2013, Pages 2111-2116

  Terazawa, Tetsuji ^a   Iwasa, Satoru ^a   Takashima, Atsuo ^a   Nishitani, Hitoshi ^a   Honma, Yoshitaka ^a   Kato, Ken ^a   Hamaguchi, Tetsuya ^a   Yamada, Yasuhide ^a   Shimada, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Cisplatin; Elderly patient; Gastric cancer; S 1

Indexed keywords

CISPLATIN; CREATININE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ABDOMINAL PAIN; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC PATIENT; HAND FOOT SYNDROME; HUMAN; KIDNEY DISEASE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PIGMENT DISORDER; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RASH; RETROSPECTIVE STUDY; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VERY ELDERLY; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE PROGRESSION; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; NEOADJUVANT THERAPY; OXONIC ACID; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 84888399055     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1537-7     Document Type: Article

References (20)

1. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063-1069
2. Chen JS, Chao Y, Hsieh RK, Cheng AL, Chen PM, Chiou TJ, Chao TY, Yeh KH, Chen LT, Whang-Peng J (2011) A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan. Cancer Chemother Pharmacol 67:1281-1289
3. Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25:1824-1831
4. Fonck M, Brunet R, Becouarn Y, Legoux JL, Dauba J, Cany L, Smith D, Auby D, Terrebonne E, Traissac L, Mertens C, Soubeyran P, Bellera C, Rainfray M, Mathoulin-Pélissier S (2011) Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: a first-line phase II study. Clin Res Hepatol Gastroenterol 35:823-830
5. Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168
6. Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, Rodin M, Panageas KS, Holland JC, Saltz L, Kris MG, Noy A, Gomez J, Jakubowski A, Hudis C, Kornblith AB (2005) Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104:1998-2005
7. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29:3457-3465
8. Kitamura K, Yamaguchi T, Taniguchi H, Hagiwara A, Yamane T, Sawai K, Takahashi T (1996) Clinicopathological characteristics of gastric cancer in the elderly. Br J Cancer 73:798-802
9. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215-221
10. Koizumi W, Akiya T, Sato A, Sakuyama T, Sasaki E, Tomidokoro T, Hamada T, Fujimori M, Kikuchi Y, Shimada K, Mine T, Yamaguchi K, Sasaki T, Kurihara M (2010) Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study. Cancer Chemother Pharmacol 65:1093-1099
11. Launay-Vacher V, Chatelut E, Lichtman SM, Wildiers H, Steer C, Aapro M, International Society of Geriatric Oncology (2007) Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 18:1314-1321
12. Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, Kim JG, Park SR, Kang WK, Shin DB, Ryu MH, Chang HM, Kim TW, Baek JH, Min YJ (2008) A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 99:584-590
13. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41
14. Nagashima F, Ohtsu A, Yoshida S, Ito K (2005) Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 8:6-11
15. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
16. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer 71:587-591
17. Seol YM, Song MK, Choi YJ, Kim GH, Shin HJ, Song GA, Chung JS, Cho GJ (2009) Oral fluoropyrimidines (Capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study. Jpn J Clin Oncol 39:43-48
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
19. Tsushima T, Hironaka S, Boku N, Machida N, Yamazaki K, Yasui H, Fukutomi A, Todaka A, Taniguchi H, Onozawa Y, Taku K (2013) Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer. Int J Clin Oncol 18:10-16
20. Xiang XJ, Zhang L, Qiu F, Yu F, Zhan ZY, Feng M, Yan J, Zhao JG, Xiong JP (2012) A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer. Chemotherapy 58:1-7